Meta Platforms
META
Coinbase
COIN
Amazon
AMZN
Apple
AAPL
Oracle
ORCL
US Stock MarketDetailed Quotes
NRIX Nurix Therapeutics
- 20.890
- -0.600-2.79%
Close Dec 3 16:00 ET
- 20.890
- 0.0000.00%
Post 18:54 ET
1.48BMarket Cap-7203P/E (TTM)
21.570High20.500Low780.20KVolume21.050Open21.490Pre Close16.34MTurnover1.35%Turnover RatioLossP/E (Static)70.84MShares29.56052wk High3.93P/B1.21BFloat Cap7.65052wk Low--Dividend TTM57.74MShs Float52.380Historical High--Div YieldTTM4.98%Amplitude4.220Historical Low20.946Avg Price1Lot Size
About Nurix Therapeutics Company
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.
Company Profile
SymbolNRIX
Company NameNurix Therapeutics
Listing DateJul 24, 2020
Issue Price19.00
Founded2009
CEODr. Arthur T. Sands, M.D.,PhD
MarketNASDAQ
Employees284
Fiscal Year Ends11-30
Address1700 Owens Street,Suite 205
CitySan Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94158
Phone1-415-660-5320
Websitehttp://www.nurixtx.com
Company Executives
- Name
- Position
- Salary
- Dr. Arthur T. Sands, M.D.,PhD
- Director, President and Chief Executive Officer
- 4.36M
- Hans van Houte
- Chief Financial Officer and Principal Accounting Officer
- 1.61M
- Dr. Gwenn Hansen, PhD
- Chief Scientific Officer
- 1.63M
- Dr. Christine Ring, J.D.,PhD
- Chief Legal Officer, Chief Compliance Officer and Secretary
- --
- Dr. David L. Lacey, M.D.
- Chairman of the Board
- 263.29K
- Anil Kapur
- Director
- --
- Judith A. Reinsdorf, J.D.
- Independent Director
- 225.79K
- Edward C. Saltzman
- Independent Director
- 223.29K
- Julia P. Gregory
- Independent Director
- 238.29K
- Paul M. Silva
- Independent Director
- 225.79K
- Dr. Lori Anne Kunkel, M.D.
- Independent Director
- 228.29K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.